by MASA | Mar 10, 2025 | Immunodeficiency Hypogammaglobulinemia, News, Rare Diseases
Deadline: March 21, 2025 Download CIIC Patient Scholarship Application 2025 : You can submit your application to your provider. CIIC Annual Patient Scholarship: Empowering PIDD and Rare Disease Patients The CIIC (Coalition of Immunology and Allergy Clinics) is proud...
by MASA | Dec 19, 2024 | Drug Updates
The U.S. Food and Drug Administration (FDA) has approved VTAMA® (tapinarof) cream, 1%, for the treatment of mild, moderate, or severe atopic dermatitis (AD) in adults and children aged 2 years and older. This approval expands the use of VTAMA, previously approved for...
by MASA | Aug 15, 2024 | Drug Updates
What is D.R.E.S.S.? Drug Reaction with Eosinophilia and Systemic Symptoms (D.R.E.S.S.) is a type of drug allergy which can occur as a reaction to a large variety of medications. Symptoms include fever, rash, facial swelling, enlarged lymph nodes and kidney or liver...
by MASA | Jul 31, 2024 | Drug Updates
The FDA approved Zoryve cream (0.15%) for mild to moderate atopic dermatitis this year for adults and children aged above 6 years old. Roflumilast cream (marketed under the name Zoryve) is a non-steroidal topical cream that is applied once daily to affected areas of...
by MASA | Apr 23, 2024 | Drug Updates, News
The U.S. Food and Drug Administration (FDA) has provided an emergency use authorization (EUA) for a new medicine called Pemgarda™ (pemivibart), aimed at preventing COVID-19 in certain high-risk individuals. This medication is specifically designed for those who are...
by MASA | Mar 31, 2024 | Drug Updates
US FDA approved of XHANCE as the first and only medication for adults with chronic rhinosinusitis without nasal polyps. It is a fluticasone propionate nasal spray which uses the Exhalation Delivery System to enable topical steroid to the inflamed areas and is proven...
